Etomidate with or without flumazenil anesthesia for stem cell transplantation in autistic children
Insights
Etomidate provides stable anesthesia for autistic children undergoing stem cell transplantation. Adding flumazenil (a reversal agent) significantly shortens recovery time without compromising safety.
Area of Science:
- Anesthesiology
- Pediatric Neurology
- Regenerative Medicine
Background:
- Autistic children undergoing stem cell transplantation require safe and effective anesthesia.
- Investigating anesthetic agents and their reversal is crucial for pediatric procedures.
Purpose of the Study:
- To evaluate the efficacy and safety of etomidate with or without flumazenil for intrathecal stem cell transplantation in autistic children.
- To compare recovery times and adverse effects between etomidate alone and etomidate with flumazenil.
Main Methods:
- A double-blind, randomized study involving 40 autistic children aged 2-12 undergoing stem cell transplantation.
- Children received etomidate, with flumazenil or placebo administered post-procedure.
- Hemodynamic parameters, sedation scores, and recovery time were monitored.
Main Results:
- Etomidate ensured stable hemodynamics and minimal adverse effects.
- Flumazenil significantly reduced recovery time and sedation scores compared to placebo.
- No significant differences in operation time or physician satisfaction were observed.
Conclusions:
- Etomidate is a safe anesthetic option for stem cell transplantation in autistic children.
- Flumazenil effectively antagonizes etomidate's effects, leading to faster recovery.
- The combination of etomidate and flumazenil is suitable for this patient population.
Background:
The aim of this study was to investigate etomidate administration with or without flumazenil in autistic children who underwent intrathecal transplantation of stem cells by lumbar puncture.
Methods:
Forty autistic children aged 2-12, who were scheduled for stem cell transplantation via lumbar puncture under anesthesia, were randomized for a double-blind study. The children were randomly assigned to two groups: the flumazenil group (group F, n=20) and the etomidate group (group E, n=20). All children received 0.2 mg/kg of etomidate. In the case of inadequate anesthesia, patients received repeated doses of 0.1 mg/kg of etomidate until reaching deep sedation. After operation, children in group F were given flumazenil (0.01 mg/kg) and children in group E received placebo. Heart rate (HR), mean arterial pressure, oxygen saturation, respiratory rate, the Ramsay sedation score (RSS), and recovery time of all children were continuously monitored and recorded during the entire procedure.
Results:
After anesthesia, blood pressure and HR measurements were not significantly changed in both groups compared with the baseline. There were no respiratory depression, bradycardia, hypotension, nausea, and vomiting. Five patients complained of pain on the site of injection. Myoclonus occurred in seven patients. Recovery time in group F was significantly shorter than in group E (p<0.001), and after the injection of flumazenil, RSS in group F significantly decreased than in group E. There were no significant differences in operation time. Physician satisfaction in both groups was similar.
Conclusions:
Etomidate resulted in stable hemodynamic responses and relatively less adverse effects, and flumazenil antagonized the anesthetic effect of etomidate; thus, etomidate with flumazenil is suitable for performing stem cell transplantation in autistic children.
